CG
CORT icon

Carmignac Gestion’s Corcept Therapeutics CORT Stock Holding History

Carmignac Gestion’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,260
Closed -$891K – 154
2024
Q3 		$891K Hold
19,260
– – 0.01% 136
2024
Q2 		$626K Buy
19,260
+2,317
+14% +$63.5K 0.01% 138
2024
Q1 		$427K Sell
16,943
-8,877
-34% -$210K 0.01% 131
2023
Q4 		$839K Hold
25,820
– – 0.01% 131
2023
Q3 		$703K Sell
25,820
-20,000
-44% -$579K 0.01% 130
2023
Q2 		$1.02M Hold
45,820
– – 0.02% 125
2023
Q1 		$992K Sell
45,820
-14,758
-24% -$324K 0.02% 112
2022
Q4 		$1.23M Buy
+60,578
New +$1.52M 0.02% 102

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Carmignac Gestion's CORT Position: Q4 2024 in Review

Carmignac Gestion sold out of Corcept Therapeutics (CORT) in Q4 2024, closing a stake of 19,260 shares — an estimated $891K sold.

Carmignac Gestion first reported a position in CORT in Q4 2022 and held it in 8 quarters. The position peaked at $1.23M in Q4 2022. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

  • Carmignac Gestion reported no remaining Corcept Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Carmignac Gestion sold 19,260 Corcept Therapeutics shares in Q4 2024, an estimated $891K.
  • Carmignac Gestion first reported a position in Corcept Therapeutics in Q4 2022 and held it in 8 quarters.
  • Carmignac Gestion's Corcept Therapeutics position peaked at $1.23M in Q4 2022.
  • 367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Carmignac Gestion's 13F filing for Q4 2024, filed 13 Feb 2025.